Sola Christopher L, Bostwick J Michael, Hart Dionne A, Lineberry Timothy W
Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.
Mayo Clin Proc. 2006 Mar;81(3):330-4. doi: 10.4065/81.3.330.
Linezolid, a novel antimicrobial with activity against gram-positive bacteria including pathogens resistant to traditional antimicrobials, also inhibits monoamine oxidase. This latter property can cause potentially lethal adverse interactions with antidepressant medications. Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome. We review the pharmacology of MAOis and describe 3 clinical situations In which linezolid-selective serotonin inhibitor (SSRI) interactions, actual or potential, figured prominently.
利奈唑胺是一种新型抗菌药物，对革兰氏阳性菌具有活性，包括对传统抗菌药物耐药的病原体，它还能抑制单胺氧化酶。后一种特性可能会与抗抑郁药物产生潜在的致命不良相互作用。精神科医生早就知道单胺氧化酶抑制剂（MAOIs）及其使用并发症，但内科和外科医生可能并不熟悉，因此可能会无意中引发高血压危象或血清素综合征。我们回顾了MAOIs的药理学，并描述了3种临床情况，在这些情况中，利奈唑胺与选择性血清素再摄取抑制剂（SSRI）之间的相互作用，无论是实际存在的还是潜在的，都非常突出。
